数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Konstantin Poukalov Director 37 未披露 未持股 2021-01-27
Roderick Wong Director 43 未披露 未持股 2021-01-27
Jean Frederic Colombel Director 64 未披露 未持股 2021-01-27
Josep Bassaganya Riera Chairman, President, Chief Executive Officer and Common Stock Director 46 176.18万 未持股 2021-01-27
Christopher Garabedian Director 54 未披露 未持股 2021-01-27

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Josep Bassaganya Riera Chairman, President, Chief Executive Officer and Common Stock Director 46 176.18万 未持股 2021-01-27
Raquel Hontecillas Chief Scientific Officer 49 90.88万 未持股 2021-01-27
Jyoti Chauhan Executive Director, Global Clinical Operations and Regulatory Compliance 32 96.14万 未持股 2021-01-27

董事简历

中英对照 |  中文 |  英文
Konstantin Poukalov

Konstantin Poukalov。 2014年起,Poukalov先生成为我们执行副总裁和首席财务官。2012-2014年,Poukalov先生担任战略运营副总裁。加入Kadmon之前,2009-2012年,Poukalov先生成为专注于在生命科学和生物技术领域Jefferies LLC医疗保健投资银行集团成员。Jefferies之前,2006-2009年,Poukalov先生是专注于保健行业UBS Investment Bank成员。Poukalov先生获得了Stony Brook University学士学位。


Konstantin Poukalov has served as a director since August 2019. Mr. Poukalov has served a Managing Director at Perceptive Advisors since March 2019 and as the Chief Business Officer of ARYA Sciences Acquisition Corp II since June 2020. He previously served as the Chief Financial Officer of Kadmon Holdings, Inc. from July 2014 to October 2018. He has served on the board of directors of Lyra Therapeutics since January 2020. Mr. Poukalov holds a B.S. in Electrical Engineering from Stony Brook University.
Konstantin Poukalov。 2014年起,Poukalov先生成为我们执行副总裁和首席财务官。2012-2014年,Poukalov先生担任战略运营副总裁。加入Kadmon之前,2009-2012年,Poukalov先生成为专注于在生命科学和生物技术领域Jefferies LLC医疗保健投资银行集团成员。Jefferies之前,2006-2009年,Poukalov先生是专注于保健行业UBS Investment Bank成员。Poukalov先生获得了Stony Brook University学士学位。
Konstantin Poukalov has served as a director since August 2019. Mr. Poukalov has served a Managing Director at Perceptive Advisors since March 2019 and as the Chief Business Officer of ARYA Sciences Acquisition Corp II since June 2020. He previously served as the Chief Financial Officer of Kadmon Holdings, Inc. from July 2014 to October 2018. He has served on the board of directors of Lyra Therapeutics since January 2020. Mr. Poukalov holds a B.S. in Electrical Engineering from Stony Brook University.
Roderick Wong
暂无中文简介

Roderick Wong has served as a director since August 2019. Dr. Wong has served as Managing Partner and Chief Investment Officer of RTW Investments, LP since 2010. Dr. Wong previously served as the President, Chief Executive Officer and Chairman of Health Sciences Acquisition Corporation from December 2018 to December 2019. He has served as Chairman of the board of directors of Rocket Pharmaceutics, Inc. since July 2015 and as a member of the board of directors of Avidity Biosciences, Inc. since June 2020. Dr. Wong holds a B.S. in Economics from Duke University, an M.D. from the University of Pennsylvania Medical School and an M.B.A. from Harvard Business School.
暂无中文简介
Roderick Wong has served as a director since August 2019. Dr. Wong has served as Managing Partner and Chief Investment Officer of RTW Investments, LP since 2010. Dr. Wong previously served as the President, Chief Executive Officer and Chairman of Health Sciences Acquisition Corporation from December 2018 to December 2019. He has served as Chairman of the board of directors of Rocket Pharmaceutics, Inc. since July 2015 and as a member of the board of directors of Avidity Biosciences, Inc. since June 2020. Dr. Wong holds a B.S. in Economics from Duke University, an M.D. from the University of Pennsylvania Medical School and an M.B.A. from Harvard Business School.
Jean Frederic Colombel
暂无中文简介

Jean Frederic Colombel has served as a director since January 2021. Dr. Colombel currently serves as a Professor of Medicine and Director of the Leona and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease, Icahn School of Medicine, New York, positions he has held since 2013. Since 2013 Dr. Colombel has also served as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine, New York. Since 2017 Dr. Colombel has served as a member of the Committee on Appointments, Promotions and Tenure at the Icahn School of Medicine, New York. Dr. Colombel has served as an associate editor of Gastroenterology since 2016 and has been a member of the National Scientific Advisory Committee at the Crohn’s & Colitis Foundation of America since 2015. Dr. Colombel holds an HDR Habilitation a Diriger les Recherches from Universite Lille II, France, a DEA (Diplome d’Etudes Approfondies) from Universite Paris VII, France, and an M.D. from Université Lille II, France.
暂无中文简介
Jean Frederic Colombel has served as a director since January 2021. Dr. Colombel currently serves as a Professor of Medicine and Director of the Leona and Harry B. Helmsley Charitable Trust Inflammatory Bowel Disease, Icahn School of Medicine, New York, positions he has held since 2013. Since 2013 Dr. Colombel has also served as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine, New York. Since 2017 Dr. Colombel has served as a member of the Committee on Appointments, Promotions and Tenure at the Icahn School of Medicine, New York. Dr. Colombel has served as an associate editor of Gastroenterology since 2016 and has been a member of the National Scientific Advisory Committee at the Crohn’s & Colitis Foundation of America since 2015. Dr. Colombel holds an HDR Habilitation a Diriger les Recherches from Universite Lille II, France, a DEA (Diplome d’Etudes Approfondies) from Universite Paris VII, France, and an M.D. from Université Lille II, France.
Josep Bassaganya Riera
暂无中文简介

Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
暂无中文简介
Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
Christopher Garabedian

Christopher Garabedian,他一直担任我们董事会的成员(2010年6月以来),以及我们的总裁兼首席执行官(2011年1月以来)。他曾担任Celgene Corporation(一体化的上市全球生物制药公司)的企业战略的副总裁(从2007年7月到2010年12月),负责评估所有潜在的商业发展事务。从2005年11月到2007年6月,他担任早期生物制药公司的独立顾问。他曾任职Gilead Sciences公司(上市生物制药公司),担任多种全球领导职务,包括公司发展副总裁、营销副总裁,以及医务副总裁(从1997年到1998年,从1999年到2005年11月)。任职Gilead Sciences公司期间,他负责管理公司发展计划,包括项目组合评估和规划、并购和授权活动,并领导四个全球产品发布。他也曾担任COR Therapeutics公司(从1998年到1999年)和Abbott Laboratories公司(从1994年到1997年)的多种商业职务。他的生物制药生涯始于担任Migliara/Kaplan Associates公司的顾问(从1991年到1994年)。


Christopher Garabedian has served as a director since September 2017. He founded Xontogeny in June 2016 and serves as its Chairman and Chief Executive Officer. Mr. Garabedian also serves as a Senior Advisor at the Boston Consulting Group, a position he has held since January 2016 and as a Portfolio Manager at Perceptive Advisors, a position he has held since May 2017. He previously served as the President and Chief Executive Officer of Sarpeta Therapeutics, Inc. from January 2011 to March 2015 as well as a member of the board of directors from June 2010 to March 2015. Mr. Garabedian earned a B.S. in Marketing from the University of Maryland.
Christopher Garabedian,他一直担任我们董事会的成员(2010年6月以来),以及我们的总裁兼首席执行官(2011年1月以来)。他曾担任Celgene Corporation(一体化的上市全球生物制药公司)的企业战略的副总裁(从2007年7月到2010年12月),负责评估所有潜在的商业发展事务。从2005年11月到2007年6月,他担任早期生物制药公司的独立顾问。他曾任职Gilead Sciences公司(上市生物制药公司),担任多种全球领导职务,包括公司发展副总裁、营销副总裁,以及医务副总裁(从1997年到1998年,从1999年到2005年11月)。任职Gilead Sciences公司期间,他负责管理公司发展计划,包括项目组合评估和规划、并购和授权活动,并领导四个全球产品发布。他也曾担任COR Therapeutics公司(从1998年到1999年)和Abbott Laboratories公司(从1994年到1997年)的多种商业职务。他的生物制药生涯始于担任Migliara/Kaplan Associates公司的顾问(从1991年到1994年)。
Christopher Garabedian has served as a director since September 2017. He founded Xontogeny in June 2016 and serves as its Chairman and Chief Executive Officer. Mr. Garabedian also serves as a Senior Advisor at the Boston Consulting Group, a position he has held since January 2016 and as a Portfolio Manager at Perceptive Advisors, a position he has held since May 2017. He previously served as the President and Chief Executive Officer of Sarpeta Therapeutics, Inc. from January 2011 to March 2015 as well as a member of the board of directors from June 2010 to March 2015. Mr. Garabedian earned a B.S. in Marketing from the University of Maryland.

高管简历

中英对照 |  中文 |  英文
Josep Bassaganya Riera
暂无中文简介

暂无中文简介
Josep Bassaganya Riera has served as our Chairman, President and Chief Executive Officer since our founding in January 2017. Dr. Bassaganya-Riera has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory since July 2002 and the Chairman of the board of directors of Biotherapeutics Inc. since October 2008. He previously served as the Chief Executive Officer of Biotherapeutics from October 2008 to September 2017 and a Research Professor of Immunology at Virginia Tech from December 2002 to May 2020. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
Raquel Hontecillas
暂无中文简介

暂无中文简介
Raquel Hontecillas has served as our Chief Scientific Officer since our founding in January 2017. Dr. Hontecillas is the Co-Director of the Nutritional Immunology and Molecular Medicine Laboratory, a position she has held since July 2002 and the Chief Scientific Officer of Biotherapeutics, Inc., a position she has held since October 2008. She previously served as a Research Professor of Immunology at Virginia Tech from July 2008 to July 2020. Dr. Hontecillas holds a degree in Veterinary Medicine from Universidad Complutense University de Madrid, Spain and a Ph.D. in Immunology from Iowa State University.
Jyoti Chauhan
暂无中文简介

暂无中文简介
Jyoti Chauhan has served as our Executive Director of Global Clinical Operations and Regulatory Affairs since August 2019. She previously served as our Clinical Project Manager from February 2018 to July 2018 and our Program Director, Clinical Operations and Regulatory Affairs from July 2018 to August 2019. Ms. Chauhan previously served as the Manager of Regulatory Affairs at NexImmune, Inc. from March 2018 to August 2018 the Senior Regulatory Affairs Specialist at the International Partnership for Microbicides from September 2017 to March 2018 and the Regulatory Affairs Specialist at Technical Resources International, Inc. from March 2016 to September 2017 and currently serves as a Principal at Nova Technology Inc., a position she has held since October 2015. Ms. Chauhan holds a B.S. in Biotechnology with Chemistry, Botany and Zoology from Hemwati Nandan Bahuguna Garhwal University and a M.S. in Pharmaceutical Sciences from the Narsee Monjee Institute of Management Studies.